Minghui Pharmaceutical
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Suite 6305 Building 6 338 Jialilue Shang...Phone Number
+86 2160898367Website
www.minghuipharma.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Minghui Pharmaceutical
Minghui Pharmaceutical Inc. is a Shanghai-based clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, immunology, and autoimmune diseases. Leveraging proprietary antibody and ADC platforms, Minghui advances a diverse pipeline through global partnerships and strategic collaborations.Explore more
Popular SearchesMinghui Pharmaceutical LtdMinghui Pharmaceutical IncSIC Code 28,283NAICS Code 32,325Show moreMinghui Pharmaceutical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Minghui Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Minghui Pharmaceutical recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Minghui Pharmaceutical
Check out if Minghui Pharmaceutical is spiking on competitors!
Funding: Get notified immidiatlly once Minghui Pharmaceutical has new funding data
Minghui Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Minghui Pharmaceutical launches new products
Check if Minghui Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Click to see if Minghui Pharmaceutical had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Minghui Pharmaceutical
Find 3 more new buyers
Company Profile Activity
Activity Insights
Minghui Pharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Minghui Pharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Minghui Pharmaceutical.
Minghui Pharmaceutical financials insights
Gather financial insights about Minghui Pharmaceutical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$131M
Minghui Pharmaceutical Tech Stack
A closer look at the technologies used by Minghui Pharmaceutical
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Minghui Pharmaceutical News & Media
Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease At 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chronic TED MHB018A was generally well tolerated among 98 treated patients, demonstrating an excellent safety profile, with all hearing-related adverse events reported as Grade 1 and no severe or permanent hearing damage MHB018A is being evaluatedMinghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today announced updated clinical data from its Phase I/II study...Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Minghui Pharmaceutical
Sign Up For FreeTo access detailed company insights
Minghui Pharmaceutical Inc. is a Shanghai-based clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, immunology, and autoimmune diseases. Leveraging proprietary antibody and ADC platforms, Minghui advances a diverse pipeline through global partnerships and strategic collaborations.... Read More
